Laura Schumacher compensation by year
AbbVie Summary Compensation Table · all 7 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Salary | $979,369 | $1,008,526 | $1,043,582 | $1,176,538 | $1,211,808 | $1,248,154 | $1,285,599 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $2,864,483 | $7,681,631 | $4,134,594 | $3,400,155 | $5,822,401 | $4,258,823 | $5,525,464 |
| Option awards | $725,663 | $980,980 | $991,720 | $859,429 | $1,390,831 | $1,061,733 | $1,299,415 |
| Non-equity incentive | $1,626,000 | $1,954,549 | $1,954,549 | $2,400,000 | $2,550,000 | $2,638,860 | $2,252,079 |
| Pension and deferred compensation | $1,627,686 | $2,957,506 | $2,739,969 | $6,579,440 | $5,716,702 | $2,912,698 | $604,070 |
| All other | $394,498 | $396,164 | $518,745 | $727,225 | $434,534 | $291,570 | $638,660 |
| Total | $8,217,699 | $14,979,356 | $11,383,159 | $15,142,787 | $17,126,276 | $12,411,838 | $11,605,287 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AbbVie Inc. DEF 14A filed March 20, 2023, accession 0001558370-23-004204, and prior-year filings. Open the filing on EDGAR.
How this page was built: the AbbVie Inc. filed document, accession 0001558370-23-004204. Every figure is read from that document and cited to the page and table it appears in. Filed March 20, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 39,928 | $6,452,764 | — |
| PSU | 35,976 | $5,814,081 | — |
| PSU | 33,043 | $5,340,079 | — |
| Option | 43,478 | — | $105.92 |
| Option | 38,188 | — | $93.50 |
| Option | 56,917 | — | $144.54 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AbbVie Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
AbbVie’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Richard Gonzalez | Chairman of the Board and Chief Executive Officer | $26,287,185 |
| Laura Schumacher · this page | Vice Chairman, External Affairs and Chief Legal Officer | $11,605,287 |
| Robert Michael | Vice Chairman and President | $9,774,369 |
| Jeffrey Stewart | Executive Vice President, Chief Commercial Officer | $9,625,119 |
| Azita Saleki-Gerhardt | Executive Vice President, Operations | $8,999,548 |
| Scott Reents | Executive Vice President, Chief Financial Officer | $5,621,936 |
The full AbbVie compensation record
free company briefThis page is one person within AbbVie's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the AbbVie proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AbbVie's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.